170 related articles for article (PubMed ID: 15360005)
1. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
Tan D; Hwang W; Ng HJ; Goh YT; Tan P
Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Cortes J; Ault P; Koller C; Thomas D; Ferrajoli A; Wierda W; Rios MB; Letvak L; Kaled ES; Kantarjian H
Blood; 2003 Jun; 101(12):4714-6. PubMed ID: 12595304
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement.
Anghel G; De Rosa L; Ruscio C; Petti N; Riccardi M; Severino A; Majolino I
Tumori; 2005; 91(1):67-70. PubMed ID: 15850007
[TBL] [Abstract][Full Text] [Related]
6. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
7. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
8. [Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha].
Pottier P; Planchon B; Grossi O
Rev Med Interne; 2003 Aug; 24(8):542-6. PubMed ID: 12888176
[TBL] [Abstract][Full Text] [Related]
9. [Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].
Wolf D; Gastl G; Rumpold H
Dtsch Med Wochenschr; 2004 Oct; 129(40):2104-6. PubMed ID: 15455302
[TBL] [Abstract][Full Text] [Related]
10. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Ault P; Cortes J; Koller C; Kaled ES; Kantarjian H
Leuk Res; 2002 Sep; 26(9):881-4. PubMed ID: 12127565
[TBL] [Abstract][Full Text] [Related]
11. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.
Pardanani A; Reeder T; Porrata LF; Li CY; Tazelaar HD; Baxter EJ; Witzig TE; Cross NC; Tefferi A
Blood; 2003 May; 101(9):3391-7. PubMed ID: 12506022
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified.
Iurlo A; Fracchiolla NS; Ferla V; Cassin R; Gottardi E; Beghini A; Gianelli U; Spinelli O; Cortelezzi A
J Clin Oncol; 2014 Apr; 32(10):e37-9. PubMed ID: 24449233
[No Abstract] [Full Text] [Related]
13. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
Coutré S; Gotlib J
Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
[TBL] [Abstract][Full Text] [Related]
14. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib.
Ikezoe T; Togitani K; Tasaka T; Nishioka C; Yokoyama A
Leuk Res; 2010 Aug; 34(8):e200-1. PubMed ID: 20303172
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
17. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
18. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib.
Frickhofen N; Märker-Hermann E; Reiter A; Walz C; Jung B; Bauer H; Hochhaus A
Ann Hematol; 2004 Jul; 83(7):477-80. PubMed ID: 14986065
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
Stone RM; Gilliland DG; Klion AD
Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]